The 12 linked references in paper E. Shishkina V., M. Barkhatov V., E. Borisova V., S. Falalaleeva O., N. Shchekaleva A., N. Makarevskaya Yu., M. Chubko A., Е. Шишкина В., М. Бархатов В., Е. Борисова В., С. Фалалеева О., Н. Щекалева А., Н. Макаревская Ю., М. Чубко А. (2016) “Митохондриальное заболевание – NARP-синдром – в практике детского невролога // THE MITOCHONDRIAL DISEASE NARP SYNDROME IN THE PRACTICE OF A PEDIATRIC NEUROLOGIST” / spz:neicon:rjdn:y:2016:i:3:p:57-61

  1. Blanco-Grau А., Bonaventura-Ibars I., CollCantí J. et al. Identification and biochemical characterization of the novel mutation m.8839G>C in the mitochondrial ATP6 gene associated with NARP syndrome. Genes Brain Behav 2013;12(8):812–20. DOI: 10.1111/gbb.12089. PMID: 24118886.
  2. Chinnery P., Marjarnaa K., Turnbull D., Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006;(1):CD004426. DOI: 10.1002/14651858.CD004426.pub2. PMID: 16437486.
  3. Chowers I., Lerman-Sagie T., Elpeleg O.N. et al. Cone and rod dysfunction in the NARP syndrome. Br J Ophthalmol 1999;83(2):190–3. DOI: 10.1136/bjo.83.2.190. PMID: 10396197.
  4. Craven L., Tuppen H.A., Greggains G.D. et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA 60 3 disease. Nature 2010;465(7294):82–5. DOI: 10.1038/nature08958. PMID: 20393463.
  5. D’Aurelio M., Vives-Bauza C., Davidson M.M. et al. Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cell. Hum Mol Genet 2010;19(2):374–86. DOI: 10.1093/hmg/ddp503. PMID: 19875463.
  6. Debray F.G., Lambert M., Lortie A. et al. Long-term outcome of Leigh syndrome caused by the NARP-T8993C mtDNA mutation. Am J Med Genet A 2007;143A(17):2046–51. DOI: 10.1002/ajmg.a.31880. PMID: 17663470.
  7. Elliott H.R., Samuels D.C., Eden J.A. et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008;83(2):254–60. DOI: 10.1016/j.ajhg.2008.07.004. PMID: 18674747.
  8. Kanabus M., Heales S.J., Rahman S. Development of pharmacological strategies for mitochondrial disorders. Br J Pharmacol 2014;171(8):1798–817. DOI: 10.1111/bph.12456. PMID: 24116962.
  9. Kerrison J.B., Biousse V., Newman N.J. Retinopathy of NARP syndrome. Arch Ophthalmol 2000;118(2):298–9. DOI: 10.1001/archopht.118.2.298. PMID: 10676807.
  10. Kisler J.E., Whittaker R.G., McFarland R. Mitochondrial diseases in childhood: a clinical approach to investigation and management. Dev Med Child Neurol 2010;52(5):422–33. DOI: 10.1111/j.1469-8749.2009.03605.x. PMID: 20163433.
  11. Paull D., Emmanuele V., Weiss K.A. et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature 2013;493(7434):632–7. DOI: 10.1038/nature11800. PMID: 23254936.
  12. Tachibana M., Amato P., Sparman M. et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013;493(7434):627–31. DOI: 10.1038/nature11647. PMID: 23103867.